secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2024-03-15T23:59:59+00:00
Accession:  0001493152-24-010097
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra reports FY2023 net loss $11.3M, cash $1.8M; advances ATR-12 Phase 1b and ATR-04 IND
--------------------------------------------------------------------------------

- Net loss $11.3M vs $10.7M in 2022; service revenue from related party $0.7M.
- Cash and equivalents $1.8M at Dec 31, 2023, plus $4.4M net from Feb 2024 follow-on.
- ATR-12 for Netherton syndrome: Phase 1b trial enrolling ~12 patients; safety data in late 2024.
- ATR-04 for EGFRi-associated rash: IND submission mid-2024; first-in-human trial by late 2024/early 2025.
- Bayer joint development agreement progressing; expect license agreement with upfront payment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/0001493152-24-010097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000149315224010097/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer